Organ Chips are microfluidic devices, developed at the Wyss, that are lined with living human cells that recapitulate the complex structures and functions of human organs. Emulate, Inc. is leveraging this tech to enable faster, better, & cheaper therapeutic development & insights into human health.

Blood Clot Dx is a microfluidic chip device that can non-invasively monitor a patient’s blood for evidence of clotting in real time. The first application will be in patients with MPM, an aggressive lung cancer. Eventually, this could be used to detect blood clots in a variety of contexts.

Wyss researchers developed a human lung alveolus chip infection model, which enables the investigation of viral replication, inflammatory responses, and genetic off-target effects of a novel pan-influenza CRISPR therapy.

Learn more about our Sustainable Futures Initiative, our latest innovations, and how we're integrated into a larger ecosystem of supporters and collaborators to find innovative solutions to the crisis facing our planet.

Join us in congratulating Core Faculty member Christopher Chen on his election to the @nationalacademies.org of Medicine! Chen is also the William F. Warren Distinguished Professor of Biomedical Engineering at @bostonu.bsky.social.

What is it really like to do research? We're demystifying life as a scientist by dispelling common myths and misconceptions, starting with the frequency of "eureka" moments.

"Charles Park is an example of the kind of bold thinker we want in the Wyss & @harvardseas.bsky.social communities. He is not only asking deep mechanistic questions but also thinking about patient impact," explains Samir Mitragotri. Park was recently named a @statnews.com Wunderkind.

This paper validates the original work establishing this concept for the cGAS-STING pathway. Kudos to the authors. @wyssinstitute.bsky.social journals.asm.org/doi/10.1128/...

Visionary talk from Jennifer Lewis yesterday at the MIT.nano Dresselhaus Lecture, highlighting opportunities for 3D printing in soft robotics & tissue engineering! You can watch the full lecture and the q&a session (moderated by me!) here: mitnano.mit.edu/events/dress... @wyssinstitute.bsky.social

Wyss and @harvardseas.bsky.social researchers have developed a novel vaccine strategy to prevent the infection of implanted orthopedic devices.

Wyss researchers developed NodeTX, a novel approach to immunotherapy that aims to leverage the human body’s innate ability to form tertiary lymphoid organs (TLOs) to fight cancer.

Nearly 60% of global greenhouse gas emissions are linked to the production and processing of meat. So, Wyss startup Tender Food, which has recently evolved into Lasso, is commercializing nanofiber-spinning technology to offer better plant-based meat alternatives and more.

Happy Halloween from the Wyss Institute 🎃

Read about our Founding Donor Hansjörg Wyss' vision of spurring progress by investing in innovation that benefits humanity and supports the people and institutions driving it forward.

In honor of Bob Ross’ birthday, the @wyssinstitute.bsky.social posted a video of George Church doing a near perfect impression of Ross…painting a happy woolly mammoth. www.instagram.com/reel/DQZnoLe...

To explore the use of CRISPR-Cas13 for developing influenza therapeutics, @wyssinstitute.bsky.social & @harvardmed.bsky.social scientists used a human lung chip infected with influenza A virus to evaluate the on-target and off-target effects of antiviral crRNA therapeutics. 🧪

Congratulations to Wyss Technology Development Fellow Ana Raquel P. Santa Maria on being awarded the "Making a Difference in Meaningful Ways Award" from WEST. This award honors women who go beyond titles and tasks to create lasting impact in their communities and workplaces.

The world’s challenges aren’t stopping. We can’t either. We’re developing solutions to the toughest problems facing people and our planet. And we’re not slowing down. Learn how you can support our mission: bit.ly/Wyss-Giving

The Wyss' Brain Targeting Program was launched in 2019 with the mission of finding a way to deliver therapies across the blood-brain barrier safely and effectively. Learn about the progress they've made, including adding new sponsors and having six licenses of their brain shuttle technologies.

Dr. Charles Park, a postdoctoral researcher in the Mitagotri lab at the @wyssinstitute.bsky.social , has been named a 2025 STAT Wunderkind by STAT News! Dr. Park’s work focuses on reprogramming #macrophages to take on #AntiCancer phenotypes. 👏 Congratulations! https://bit.ly/4oAT1w9

In 2021, Unravel Biosciences licensed CogniXense to identify and create drugs to treat central nervous system disorders like Rett syndrome. This year, they received approval for their first human clinical trial to test a disease-modifying drug for Rett syndrome. #RettSyndromeAwarenessMonth

Wyss researchers have discovered a new class of immunostimulatory double-stranded RNAs (dsRNAs) that produce anti-cancer and pan-antiviral activity by inducing the expression of multiple types of interferons, the drivers of the innate immune system.

Last week, we published our 2025 Impact Report: A Force of Nature. We’re so proud to share the numerous advances our community has made over the last year. See how we're fulfilling our mission of transforming healthcare and the environment, and learn how you can get involved.

Learn more about Associate Faculty member Michael Levin in this installment of the 20-ish Questions series, which shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. #Wyss20ishQs #UniquelyWyss

You wouldn’t eat a new snack without a nutrition label on the package listing the ingredients. Haritosh Patel wants the same to be true for the air you breathe. He’s developing an indoor air quality sensor inspired by the way dogs smell. Learn more about Haritosh & his work in this month’s #HOWyss.

Congrats to Core Faculty member Chris Chen on his election to the @nationalacademies.org, one of the highest honors in health and medicine. Through his work at the Wyss and @bostonu.bsky.social, Chen has advanced our understanding of how cells sense and respond to their physical microenvironment.

Transforming breakthrough science, like the use of CRISPR-Cas9 for precise targeted gene editing in mammalian cells, into a cascade of innovations, like genetically modified pig kidneys that can be transplanted into humans – that’s the power of the Wyss Effect. #WorldCRISPRDay bit.ly/3R5VX59

Congrats to Postdoc, Charles Park, on being named a 2025 STAT Wunderkind by @statnews.com! Park, partially inspired by his mother's cancer diagnosis, is recognized for his work on reprogramming macrophages to take on anti-cancer phenotypes & sustaining their activity even in pro-tumor environments.

The Wyss Translational AI Catalyst is an institute-wide effort designed to enable and accelerate innovation through effective and responsible application of new computational approaches while leveraging machine learning algorithms to generate unique biological datasets.

Wyss startup Gameto is commercializing ovarian organoid technology developed here to address infertility by offering a safer, more cost-effective method of maturing female eggs for IVF. Gameto is preparing for Phase 3 clinical trials in the United States.

PFAS exposure has been linked to cancers, liver damage, immune dysfunction, & developmental issues. Despite the scale of contamination, testing is expensive & slow. Wyss researchers developed PFASense, a portable, protein-based biosensor device that makes PFAS detection simple, fast, & affordable.

Congratulations to Wyss Lumineers Surge Biswas and Frances Anastassacos on their startup Nabla Bio signing a second, larger multi-year collaboration with Takeda. The partnership deploys Nabla's proprietary AI platform, Joint Atomic Model (JAM), broadly across Takeda's early discovery portfolio.

Full paper available to read via #OpenAccess: pubs.rsc.org/en/content/a... Preclinical assessment of pan-influenza A virus CRISPR RNA therapeutics in a human lung alveolus chip Donald E. Ingber et al @wyssinstitute.bsky.social

In a new Wyss study, a CRISPR antiviral therapeutic and a flu virus walk into a Human Organ Chip…and it turns out that Human Organ Chip technology is a superior tool for assessing pan-influenza A CRISPR RNA therapies to fight future flu pandemics.

My postdoc work is now on bioRxiv! We combined engineered bacteria and hydrogels to create implantable living materials that safely confine bacteria while letting them sense disease and release drugs from within. 🔗 www.biorxiv.org/content/10.1...

NASA’s next lunar mission will include Organ Chips provided by Wyss startup Emulate Inc. as part of the AVATAR experiment. The Chips will contain cells grown from the blood plasma of the astronauts, and will be compared with a control group of Chips that remain on Earth.

We're so proud to share that Wyss Events Coordinator, Ana Carolina Villar de Jimenez, was named one of the ALX100, which recognizes exceptional Latino American leaders across MA who have demonstrated excellence & made significant contributions to their fields and communities. #HispanicHeritageMonth

DoriVac is a DNA origami platform that enables the precise spacing and geometrical arrangement of molecules, including adjuvants and antigens, on nanoparticles to produce highly effective and personalized immunotherapies.

Wyss researchers have developed a novel tunable biomaterial system that allows researchers to investigate and leverage the effects of tissue mechanics on the state of therapeutic T cells in vitro.

Knowing she was one of the first babies conceived through IVF in Peru sparked curiosity about biology in Ela Contreras-Panta. Over time, that evolved into a commitment to biomedical research. Read her reflections on science's role in her life and the way it connects people. #HispanicHeritageMonth

We are looking for a motivated Research Assistant II to contribute to a multidisciplinary portfolio of research projects involving procedures of health monitoring, injections, blood sampling, survival surgery, post-operative care, & behavioral studies.

Researchers at the Wyss have developed DNA Nanoswitch Calipers, a method for identifying and measuring post-translational modifications on proteins, which could unlock profound advances in our understanding of health and disease, as well as biomedicine. #NanoDay

Inspired by the lotus leaf, researchers at the Wyss and @harvardseas.bsky.social developed Nixe, a PFAS-free water-repellent coating solution that doesn't compromise fabric breathability, durability, or flexibility. #SustainableFutures #PFAS #GreenTech

Wyss researchers developed ReConstruct, an approach that creates living tissue implants from a patient's own cells that can be integrated into their body to offer cancer survivors a more natural, safer reconstruction option following a mastectomy. #BreastCancerAwarenessMonth

We are looking for a Senior Manager of Donor Relations to strategically grow and manage a growing portfolio of new prospects and donors. In this role, you will be a key contributor to expanding the donor base and strengthening stewardship practices that align with the Institute’s strategic goals.

Sepsis is a life-threatening condition, & the third leading cause of neonatal mortality worldwide. Current sepsis diagnostics rely on blood draws that can take days to deliver results. So, Wyss researchers are developing Neosense, a faster & more accurate method for diagnosing sepsis using saliva.

The HarborSite platform overcomes key limitations in current gene therapy approaches by combining two genome editing technologies: genomic safe harbors and highly effective recombinases. Combined, these could enable more predictable, safe, and durable future gene therapies.

Our team is developing injectable immune organs (iNodes) that aim to boost immune responses to enable the formation of lymphoid organs and improve ovarian cancer survival rates by at least 50%. This innovative approach may also benefit other cancers and diseases.

In this podcast interview, the Wyss' Peter Nguyen explores how synthetic biology can turn biofilms into useful materials, embed cell-free systems into wearables, & program probiotics as future therapeutics. He discusses the philosophy behind bioengineering, iGEM, & ideas to tackle plastic pollution.

🩸 The @wyssinstitute.bsky.social has received Wellcome Leap funding to develop the first-ever human Organ Chip model for heavy menstrual bleeding. This work led by Dr. Don Ingber could transform our understanding of #ReproductiveHealth and lead to better treatments. See more: https://bit.ly/3KBzcGe